Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.54 |
| ▸ | LPL | P06858 | 7/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18620920 | 0.85 | QDPR (0.47) | QDPRLPLLIPG | |
| SCHEMBL27160076 | 0.82 | LPL (0.45) | QDPRLPLLIPG | |
| SCHEMBL4154520 | 0.81 | QDPR (0.40) | QDPR | |
| SCHEMBL24802975 | 0.80 | SLC6A4 (0.41) | QDPRLPLLIPG | |
| SCHEMBL22807059 | 0.80 | QDPR (0.48) | QDPR | |
| SCHEMBL18372246 | 0.80 | LIPG (0.43) | QDPRLPLLIPG | |
| SCHEMBL28513402 | 0.79 | HTR6 (0.38) | QDPR | |
| SCHEMBL16795094 | 0.79 | LPL (0.42) | LPLLIPG | |
| SCHEMBL31223021 | 0.79 | QDPR (0.44) | QDPR | |
| SCHEMBL28905293 | 0.79 | SLC6A4 (0.42) | QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20220411404-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| EP-4058015-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115066240-A | Allosteric EGFR inhibitors and methods of use thereof | 达纳-法伯癌症研究所股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2021096948-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2016107541-A1 | PYRROLE AMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 成都先导药物开发有限公司 | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | QDPR 4364/4885LPL 4016/4885LIPG 3830/4885 |
| US-20220411404-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | QDPR 3222/4885LPL 2919/4885LIPG 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.